Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-14
DOI
10.1186/s40425-019-0800-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Overall survival after treatment for metastatic uveal melanoma
- (2019) Elina S. Rantala et al. MELANOMA RESEARCH
- Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
- (2019) Meredith Pelster et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab
- (2019) Kenjiro Namikawa et al. MELANOMA RESEARCH
- Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
- (2019) L Khoja et al. ANNALS OF ONCOLOGY
- Pembrolizumab as first-line treatment for metastatic uveal melanoma
- (2019) Ernesto Rossi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Evolutionary routes in metastatic uveal melanomas depend on MBD4 alterations.
- (2019) Manuel Rodrigues et al. CLINICAL CANCER RESEARCH
- Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors
- (2018) Manuel Rodrigues et al. Nature Communications
- Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients
- (2018) Michael Constantin Kirchberger et al. Oncotarget
- How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma
- (2018) Theresa Steeb et al. EUROPEAN JOURNAL OF CANCER
- Digital PCR-Based T-cell Quantification–Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma
- (2018) Mark J. de Lange et al. MOLECULAR CANCER RESEARCH
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- SMR Congress 2018 Abstracts
- (2018) Pigment Cell & Melanoma Research
- Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
- (2017) Markus V. Heppt et al. EUROPEAN JOURNAL OF CANCER
- Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands
- (2016) M. K. van der Kooij et al. ACTA ONCOLOGICA
- Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
- (2016) Alain P. Algazi et al. CANCER
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- The use of pembrolizumab for the treatment of metastatic uveal melanoma
- (2016) Lisa A. Kottschade et al. MELANOMA RESEARCH
- Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
- (2016) Ioannis Karydis et al. OncoImmunology
- Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
- (2015) Lisa Zimmer et al. Journal of Translational Medicine
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe
- (2011) S. Mallone et al. EUROPEAN JOURNAL OF CANCER
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started